Sensei Biotherapeutics, Inc.

NasdaqGM:SNSE Rapporto sulle azioni

Cap. di mercato: US$12.3m

Sensei Biotherapeutics Gestione

Gestione criteri di controllo 2/4

Sensei Biotherapeutics' CEO is John Celebi, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is $1.01M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $30.63K. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

Informazioni chiave

John Celebi

Amministratore delegato

US$1.0m

Compenso totale

Percentuale dello stipendio del CEO52.6%
Mandato del CEO6.8yrs
Proprietà del CEO0.2%
Durata media del management1.9yrs
Durata media del Consiglio di amministrazione3.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14
We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16
Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di John Celebi rispetto agli utili di Sensei Biotherapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$32m

Dec 31 2023US$1mUS$532k

-US$34m

Sep 30 2023n/an/a

-US$39m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$2mUS$513k

-US$49m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$42m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$7mUS$487k

-US$37m

Sep 30 2021n/an/a

-US$33m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$2mUS$395k

-US$20m

Compensazione vs Mercato: John's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD655.65K).

Compensazione vs guadagni: John's compensation has been consistent with company performance over the past year.

AMMINISTRATORE DELEGATO

John Celebi (52 yo)

6.8yrs

Mandato

US$1,012,289

Compensazione

Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
John Celebi
President6.8yrsUS$1.01m0.25%
$ 30.6k
Edward Van der Horst
Chief Scientific Officer1.9yrsUS$739.08k0.14%
$ 17.4k
Josiah Craver
Senior VP of Financeless than a yearNessun datoNessun dato
Lora Pike
Vice President of Investor Relations & Communicationsno dataNessun datoNessun dato
Christopher Gerry
Senior VP2.3yrsNessun datoNessun dato
Stephanie Krebs
Chief Business Officerless than a yearNessun datoNessun dato
Aaron Weitzman
Chief Medical Officerno dataNessun datoNessun dato

1.9yrs

Durata media

50yo

Età media

Gestione esperta: SNSE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
John Celebi
President6.8yrsUS$1.01m0.25%
$ 30.6k
Thomas Ricks
Independent Director8.9yrsUS$75.56k1.35%
$ 166.3k
William Ringo
Independent Chairman2.7yrsUS$101.57k0.063%
$ 7.8k
Robert Holmen
Independent Director7.8yrsUS$73.39k0.084%
$ 10.4k
Richard Ulevitch
Member of Immuno-Oncology Advisory Board3.5yrsNessun datoNessun dato
Deneen Vojta
Independent Director3.8yrsUS$69.32k0.018%
$ 2.2k
James Peyer
Independent Director4.8yrsUS$68.43kNessun dato
Alain Algazi
Member of Immuno-Oncology Advisory Boardno dataNessun datoNessun dato
Maura Gillison
Member of Immuno-Oncology Advisory Board3.5yrsNessun datoNessun dato
Kristian Humer
Independent Director3.3yrsUS$62.24k0.018%
$ 2.2k
Sara Pai
Member of Immuno-Oncology Advisory Boardno dataNessun datoNessun dato
Robert Schreiber
Member of Immuno-Oncology Advisory Boardno dataNessun datoNessun dato

3.8yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: SNSE's board of directors are considered experienced (3.8 years average tenure).